ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$92.04▲ +2.87%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Rhythm Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Rhythm Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Rhythm Pharmaceuticals a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $85.34 and $98.91; in 9 out of 10, between $74.87 and $112.74. Estimated annual volatility is 31%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $6.4B
- 52-week high
- $122.20
- 52-week low
- $74.50
- Revenue (12 months)
- $240M
- Revenue growth (YoY)
- +45.8%
- Gross margin
- 89.7%
- Operating margin
- -101.2%
- Net margin
- -103.6%
- Return on equity
- -117.0%
- Free cash flow (12 months)
- $-131M
- Beta
- 1.97
What this means
ATLAS does not publish a fair value for RYTM right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks RYTM has traded between $74.50 and $122.20. Today it is 24.7% below that high and 24% above its low.
On the business: revenue grew 45.8% year over year; net margin is 103.6%.
Its beta is 1.97: it tends to move more than the market, both up and down.
About the company
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases.
Want to see everything about Rhythm Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Rhythm Pharmaceuticals do?
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases.
What is the chance RYTM goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, RYTM ends the month between $85.34 and $98.91.
How big is Rhythm Pharmaceuticals and what is its P/E ratio?
Rhythm Pharmaceuticals's market capitalization is $6.4B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is RYTM?
ATLAS estimates annual volatility at 31%. In a typical month, half of the outcomes end between $85.34 and $98.91.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer